Betamethasone / clotrimazole

Selected cream and lotion are labeled for symptomatic inflammatory tinea pedis, cruris and corporis caused by Epidermophyton floccosum, Trichophyton mentagrophytes or T. rubrum in patients 17 and older. This is a topical antifungal plus potent corticosteroid, not a stand-alone antifungal or a routine eczema/diaper-rash product. Candida, scalp/nail disease and every unidentified rash are not established indications of these selected labels.

The lotion label explicitly notes that an antifungal without a steroid can treat infections without steroid-associated risks, especially noninflammatory tinea. Cream early symptom-response studies do not prove every combination is preferable to antifungal monotherapy. Lotion-versus-clotrimazole and cream-versus-lotion comparative efficacy were not studied; do not infer vehicle equivalence or universal first-line priority.

Apply a thin film twice daily for one week for tinea corporis/cruris; for tinea pedis apply twice daily for two weeks. Reassess the diagnosis if improvement is absent at these points. Do not exceed two weeks for body/groin or four weeks for feet; do not use more than 45 g/week. These maximum durations are not automatic instructions to extend every course.

Shake well, gently massage into the affected area morning and evening. The selected lotion leaflet recommends two weeks for body/groin and four weeks for feet, while the professional label caps these same durations. Reassess absent improvement after one week for body/groin or two weeks for feet. Do not exceed 45 mL/week. Do not substitute the cream’s initial course wording or convert the volume limit into an unsupported gram estimate.

Use externally on skin; avoid eyes, mouth and intravaginal use. Apply sparingly in the groin with loose clothing. The cream specifically says not to use on face or underarms. Avoid diapers/plastic pants and bandages/wrapping that occlude treatment; wash hands after cream application. Do not repeat prolonged courses for recurrent symptoms without diagnostic review.

No validated renal or hepatic numeric dose-adjustment table is provided. Liver failure, damaged skin, large area, prolonged treatment and young age can increase systemic steroid risk. If HPA suppression is documented, the clinician may gradually withdraw, reduce frequency or change to a less potent steroid; this is not a license to extend an otherwise limited antifungal/steroid course.

The selected current cream §4 lists no formal contraindications; this does not erase its age, site and duration restrictions or hypersensitivity assessment. The selected lotion formally contraindicates sensitivity to clotrimazole, betamethasone, other corticosteroids/imidazoles or any ingredient. Preserve this label difference and stop for concerning allergy/irritation rather than assuming no contraindications applies to both vehicles.

Neither reviewed topical label has a formal boxed warning. Potent-steroid endocrine effects, local atrophy, pediatric restrictions and treatment limits remain clinically significant. No oral or injectable corticosteroid safety regimen is transferred to this skin combination.

Possible local effects include burning/stinging, tingling, dryness, rash, swelling, irritation and secondary infection. Steroid-associated effects include thinning skin, stretch marks, altered pigment, fragile vessels and contact dermatitis; systemic adrenal effects can occur. Cream postmarketing reports include visual disorders. Product- and study-specific frequencies do not quantify risk for every user or vehicle.

Tell the clinician about oral/injected/inhaled steroids and other steroid-containing creams or scalp products before combining. Multiple corticosteroid products may increase total glucocorticoid exposure. Do not independently stop medically essential systemic steroids; reconcile the full regimen and skin indication.

Neither selected label provides a validated CYP-based interaction-adjustment algorithm for the combination. That is a data limit, not proof of no interactions. Occlusive dressings and other practices that change skin absorption increase toxicity risk; do not add them or another medication to the treated site without clinical direction.

Use below 17 is not recommended. Adolescent studies reported substantial adrenal suppression; children’s higher surface-area-to-body-mass ratio increases systemic risk. Diaper-area treatment is not recommended at any age. Older adults may be more sensitive, with reported atrophy/ulceration; use particular caution on thin skin and avoid occlusion.

The combination lacks a validated renal/hepatic adjustment schedule. Topical corticosteroids can be systemically absorbed, metabolized in the liver and excreted via kidneys/bile; liver failure is a cream-label HPA-suppression risk factor. Limit area and duration under clinician direction rather than invent a renal percentage reduction.

Human topical-combination data are insufficient to define fetal risk. Current cream labeling notes observational concern for low birthweight with potent topical steroids; use the smallest necessary area for the shortest necessary time after clinician review. Older lotion animal/category language does not prove human safety or a numerical risk. The oral/vaginal clotrimazole experience cannot establish this potent-steroid combination safe for unrestricted skin use.

Human milk and infant-effect data after topical combination use are lacking; systemic steroid absorption remains possible. Weigh feeding benefits and maternal treatment need, limit area/duration and prevent direct infant contact with treated skin. The cream explicitly instructs no nipple/areola application. Do not infer zero exposure or use the combination as a routine nipple antifungal.

Clotrimazole inhibits fungal lanosterol demethylation, disrupting ergosterol synthesis. Betamethasone is a corticosteroid acting on inflammatory signaling; a complete mechanism for combination tinea treatment is not defined. Vasoconstrictor testing places these combinations in a high-potency steroid range, but blanching results do not prove therapeutic equivalence.

Combination-specific skin penetration/systemic absorption have not been fully studied. Normal or inflamed skin can absorb corticosteroid, and occlusion increases uptake. Absorbed steroid undergoes hepatic metabolism and renal/biliary elimination. No established combination half-life supports a more frequent application schedule. Lotion studies versus vehicle and cream studies versus components answer different questions; one vehicle’s pharmacokinetic or efficacy findings cannot automatically substitute for the other.

Assess the diagnosis, inflammatory features, treated area, skin integrity, duration and concurrent steroids. Lack of response warrants diagnostic review, with mycological testing when appropriate. Examine for irritation/atrophy and secondary infection; consider HPA-axis testing in higher-risk exposure or suspected suppression. Labels discuss ACTH testing and the lotion also morning/urinary cortisol, but do not mandate universal testing for every short localized course.

Use only for the diagnosed condition for the prescribed course; symptom improvement does not justify sharing or repurposing it. Record start/review/stop dates, apply the correct vehicle quantity and avoid tight coverings. Contact the clinician for no improvement at one week (body/groin) or two weeks (feet), recurrent infection, significant irritation, skin thinning or visual symptoms. Serious allergy or suspected endocrine illness needs prompt assessment.

Selected Remedy Repack/Taro cream is smooth white, 45 g per tube, NDC 70518-2352-00. Selected Taro lotion is opaque white in a 30 mL bottle, NDC 51672-1308-3. Verify the dispensed manufacturer and vehicle; the familiar Lotrisone brand name alone does not confirm today’s package or formulation.

Both selected products are labeled 1% clotrimazole / 0.05% betamethasone-equivalent. Each gram contains clotrimazole 10 mg and betamethasone dipropionate 0.64 mg, equivalent to betamethasone 0.5 mg. Do not describe the salt as 0.5 mg or apply the cream gram limit to lotion milliliters. These are prescription skin products, not vaginal, ophthalmic or systemic formulations.

Store the selected cream and lotion at 20–25°C. The lotion must remain upright and be shaken well before every use. Keep containers closed, follow the actual package expiry and keep away from children. No universal refrigeration, compounded beyond-use interval or post-opening expiry is established by these labels.